Provided by Tiger Trade Technology Pte. Ltd.

Warrior Met Coal LLC

108.24
+1.171.09%
Pre-market: 107.70-0.5400-0.50%08:57 EDT
Volume:612.79K
Turnover:66.51M
Market Cap:5.69B
PE:26.02
High:110.50
Open:109.05
Low:107.91
Close:107.07
52wk High:111.20
52wk Low:54.66
Shares:52.57M
Float Shares:51.78M
Volume Ratio:1.07
T/O Rate:1.18%
Dividend:0.32
Dividend Rate:0.30%
EPS(TTM):4.16
EPS(LYR):1.08
ROE:10.04%
ROA:5.17%
PB:2.48
PE(LYR):100.22

Loading ...

Warrior Met Coal Q1 EPS $1.37 Beats $1.16 Estimate, Sales $458.588M Miss $465.987M Estimate

Benzinga Earnings
·
May 01

Warrior Met Coal Inc: Trade Restrictions With China Persist, Global Supply Continues to Pressure Pricing

THOMSON REUTERS
·
May 01

Warrior Met Coal Inc - Reaffirms Full Year 2026 Guidance

THOMSON REUTERS
·
May 01

Warrior Met Coal Q1 EPS USD 1.37

THOMSON REUTERS
·
May 01

Warrior Met Coal price target lowered to $117 from $120 at B. Riley

TIPRANKS
·
Apr 30

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

GlobeNewswire
·
Apr 30

Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire
·
Apr 27

HCC Wins Rs 2,917 Crore CIDCO Water Infrastructure Contract in Joint Venture

TIPRANKS
·
Apr 24

Earning Preview: Warrior Met Coal LLC this quarter’s revenue is expected to increase by 67.57%, and institutional views are bullish

Earnings Agent
·
Apr 23

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies

GlobeNewswire
·
Apr 21

Warrior Met Coal Keeps Quarterly Dividend at $0.08 per Share, Payable May 7 to Holders of Record May 1

MT Newswires Live
·
Apr 21

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

GlobeNewswire
·
Apr 21

Warrior Met Coal declares $0.08 quarterly cash dividend

Reuters
·
Apr 21

Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC

prnewswire
·
Apr 13

Warrior Met Coal (HCC) Valuation Check After Sector Weakness And Analyst Downgrade

Simply Wall St.
·
Apr 13

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results

GlobeNewswire
·
Apr 09

Warrior Met Coal (HCC) Receives a Hold from RBC Capital

TIPRANKS
·
Apr 09

Press Release: Warrior Sets Date for First Quarter 2026 Earnings Announcement and Investor Conference Call

Dow Jones
·
Apr 08

Do Analyst Downgrades And Weaker Coal Outlook Change The Bull Case For Warrior Met Coal (HCC)?

Simply Wall St.
·
Apr 04

Press Release: Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Apr 02